ProCE Banner Activity

CE / CME

Community Practice Grand Rounds: Experts Explore the Latest Evidence and Guideline Updates in Chronic Lymphocytic Leukemia

Video

In this certified on-demand webcast, an expert discusses the importance of individualizing the treatment and management of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) based on evidence from key clinical trials and aligning clinical practice with current guidelines to optimize patient care.

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Registered Nurses: 1.00 Nursing contact hour

Physician Assistants: maximum of 1.00 hour of AAPA Category 1 CME credit

Pharmacists: 1.00 contact hour (0.1 CEUs)

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Released: April 22, 2025

Expiration: October 21, 2025

Share

Provided by

Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

This activity is supported by educational grants from AstraZeneca and Lilly. This activity is supported by an independent medical education grant from AbbVie.

AbbVie

AstraZeneca

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurse practitioners, physician associates, oncology nurses, pharmacists, and other healthcare professionals involved in the management of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Program Learning Goal

This activity aims to improve learners’ knowledge, competence, and performance in treating patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Select first-line therapy for treatment-naive CLL/SLL, taking into consideration available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration, and patient preference

  • Appraise intraclass differences in selectivity, binding, efficacy, and adverse event profiles of agents used to treat CLL/SLL with the similar mechanism of action

  • Plan individualized treatment approaches for relapsed/refractory CLL/SLL, based on optimal sequencing strategies recommended in the NCCN Guidelines (eg, assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for therapy)​

  • Evaluate emerging data for CLL/SLL across the disease spectrum, including novel combinations, non-covalent reversible BTK inhibitors, and CAR T-cell therapy

Disclosure

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose all financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships. In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.​

Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the financial relationships listed for these individuals have been mitigated.

Farrukh T. Awan, MD, MS, MBA: consultant/advisor/speaker: AbbVie, Adaptive Biotechnologies, ADCT Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Dava Oncology, Genmab, Incyte, Kite, Loxo Oncology; researcher: AbbVie/Pharmacyclics.

NCCN and CCO Staff Disclosures
None of the planners or content peer reviewers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 22, 2025, through October 21, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

NCCN designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1 medical knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.

For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records. By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to ABIM via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1 pharmacotherapeutic contact hour for nurses.

Continuing Pharmacy Education

NCCN designates this application-based continuing education activity for 1 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-25-038-H01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until October 21, 2025. PAs should only claim credit commensurate with the extent of their participation.

ILNA
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

Click here for a list of available ILNA points. Total ILNA points available: 1.0

Disclaimer: ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.